[Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors].
In more than 40% of patients with fibromyalgia a marked influence on the pain in the skeletal system with a decrease of the tenderness at "tenderpoints" can be achieved by blocking the 5-HT3-receptors with ondansetron or tropisetron-hydrochloride. Physical complaints and vegetative signs also improve. It is discussed if patients not responding to therapy with ondansetron or tropisetron-hydrochloride have to be discriminated as a subgroup of fibromyalgia. More investigations are needed to confirm the described effects.
Stratz
T
T
Hochrhein-Institut für Rehabilitationsforschung, Bad Säckingen.
Schochat
T
T
Hrycaj
P
P
Lacki
J
J
Mennet
P
P
Färber
L
L
Schweiger
C
C
Müller
W
W
D000082:Acetaminophen / Q000009:adverse effects / Q000627:therapeutic use; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005356:Fibromyalgia / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D017294:Ondansetron / Q000009:adverse effects / Q000627:therapeutic use*; D010147:Pain Measurement; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000502:physiology; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000077526:Tropisetron
D007211:Indoles; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D000082:Acetaminophen; D017294:Ondansetron; D000077526:Tropisetron
Die Therapie der generalisierten Tendomyopathie (Fibromyalgie) durch Blockierung der 5-HT3-Rezeptoren.